news

Sytheon has published a study in the Journal of Investigative Dermatology

Sytheon has published a study in the Journal of Investigative Dermatology, profiling mechanistic details of Isosorbide Di-(Linoleate/Oleate) & supporting its effectiveness for the treatment of xerotic pruritic skin

The breakdown of the epidermal barrier and consequent loss of skin hydration is a feature of skin aging and eczematous dermatitis. Few treatments, however, resolve these underlying processes to provide full symptomatic relief.

Sytheon has evaluated topical effects of patented isosorbide di-(linoleate/oleate) (IDL) and compared with those of ethyl linoleate/oleate (doi:10.1016/j.jid.2020.09.029 ). Both IDL and ethyl linoleate/oleate downregulated inflammatory gene expression, but IDL more effectively upregulated the expression of genes associated with keratinocyte differentiation (e.g., KRT1GRHL2SPRR4). Consistent with this, IDL increased the abundance of epidermal barrier proteins (FLG and involucrin), hydration biomarker protein AQP-9, and prevented cytokine-mediated stratum corneum degradation. IDL also downregulated the expression of unhealthy skin signature genes linked to the loss of epidermal homeostasis and uniquely repressed an IFN-inducible coexpression module activated in multiple skin diseases, including atopic dermatitis & psoriasis. These results demonstrate mechanisms by which IDL improves skin hydration and epidermal barrier function, supporting IDL as an effective intervention for the treatment of xerotic pruritic skin.

Having secured broad patent coverage, defining the mechanism of IDL, and demonstrating its potential superiority over other linoleates, Sytheon stakes claim through its sister company, Symbionyx Pharmaceu­ticals Inc., to delve into the dermatological market.

 

For more information, please contact: info@sytheonltd.com

Sytheon’s CEO to Speak at NYSCC Acne Care Symposium

Sytheon’s CEO to Speak at NYSCC Acne Care Symposium

Ratan K. Chaudhuri, Ph.D., President and CEO at Sytheon, will discuss key strategic targets for mitigating acne-affected skin. Sytheon, a...

by Drew FrantzenMay 19, 2023
Read More
Sytheon is excited to announce a publication on Synergistic…

Sytheon is excited to announce a publication on Synergistic…

Sytheon is excited to announce a publication on Synergistic Anti-Inflammatory Effects of Isosorbide Fatty Acid Diesters in Cytokine-Induced Tissue Culture...

by hostingagencyusDecember 6, 2022
Read More
Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10…

Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10…

Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10 inspiring business leader by Inc. magazine to...

by hostingagencyusOctober 6, 2022
Read More
Sytenol® A is Accepted for Use in the Chinese Market

Sytenol® A is Accepted for Use in the Chinese Market

We are pleased to announce that Sytenol® A (Bakuchiol) has been successfully notified as a medium-low risk new cosmetic ingredient...

by hostingagencyusAugust 31, 2022
Read More
Sytheon Announces Relocation and Expansion of New Corporate Headquarters

Sytheon Announces Relocation and Expansion of New Corporate Headquarters

Sytheon relocates its headquarters to 10 Waterview Blvd, Parsippany, NJ. The move to a new state-of-the-art facility stems from Sytheon’s...

by hostingagencyusAugust 1, 2022
Read More
Bakuchiol – A natural alternative to Retinol shows holistic treatment approach…

Bakuchiol – A natural alternative to Retinol shows holistic treatment approach…

Bakuchiol – A natural alternative to Retinol shows holistic treatment approach for facial aging based on its multidirectional activity Beiersdorf...

by hostingagencyusJune 3, 2022
Read More